Dr. Gajewski serves as an editor for Cancer Research and Journal for Immunotherapy of Cancer. In addition, he is immediate past president of the Society for Immunotherapy of Cancer and has served on the program committees for the American Society for Clinical Oncology (ASCO) and the American Association for Cancer Research (AACR).
Specialties
Areas of Expertise
- Immunotherapy
- Melanoma
Board Certifications
- Medical Oncology
Memberships & Medical Societies
- American Association for Cancer Research
- Society for Immunotherapy of Cancer
- American Society of Clinical Oncology
- American Association of Immunologists
Practicing Since
- 1993
Languages Spoken
- English
Medical Education
- University of Chicago Pritzker School of Medicine
Residency
- University of Chicago Medicine
Fellowship
- University of Chicago Medicine
News & Research
View Published Papers- Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)
- Safety Study of SEA-CD40 in Cancer Patients
- High-Dose Recombinant Interferon Alfa-2B, Ipilimumab, or Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery
- Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery
- A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma
- PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma
- Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma
- Dacarbazine and Ipilimumab vs. Dacarbazine With Placebo in Untreated Unresectable Stage III or IV Melanoma
- A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma
- Efficacy Study of Nivolumab Compared to Ipilimumab in Prevention of Recurrence of Melanoma After Complete Resection of Stage IIIb/c or Stage IV Melanoma
- An Investigational Immuno-therapy Study of BMS-986205 Combined With Nivolumab, Compared to Nivolumab by Itself, in Patients With Advanced Melanoma
- Pembrolizumab and Ipilimumab After Prior Immunotherapy for Melanoma
- Aetna HMO (specialists only)
- Aetna POS
- Aetna PPO
- BCBS Blue Precision HMO (specialists only)
- BCBS HMO (HMOI) (specialists only)
- BCBS PPO
- Cigna HMO
- Cigna POS
- Cigna PPO
- CountyCare *see insurance page
- Aetna Better Health *see insurance page
- Medicare
- Multiplan PPO
- PHCS PPO
- United Choice Plus POS/PPO
- United Options (PPO)
- United Select (HMO & EPO) (specialists only)
- United W500 Emergent Wrap
- Aetna Medicare Advantage HMO & PPO
- BCBS Medicare Advantage HMO & PPO
- Humana Medicare Advantage Choice PPO
- Humana Medicare Advantage Gold Choice PFFS
- Humana Medicare Advantage Gold Plus HMO
- United Choice HMO (specialists only)
- University of Chicago Health Plan (UCHP)
Our list of accepted insurance providers is subject to change at any time. You should contact your insurance company to confirm UChicago Medicine participates in their network before scheduling your appointment. If your insurance company is not listed here, or if you have any other questions, please contact Managed.Care@uchospitals.edu.
Duchossois Center for Advanced Medicine (DCAM) - Hyde Park
Request an Appointment at Duchossois Center for Advanced Medicine (DCAM) - Hyde Park
To Refer a Patient
Refer a Patient
